THE UNITED STATES OF AMERICA;THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES;THE JOHNS HOPKINS UNIVERSITY; AS REPRESENTED BY THE SECRETARY; DEPARTMENT OF HEALTH & HUMAN SERVICES
The present disclosure relates to attenuated Zika viruses and vaccines, attenuated chimeric Zika viruses and vaccines, and to multivalent immunogenic compositions comprising Zika vaccines and vaccines to other flavi viruses. The chimeric Zika viruses includes a first nucleotide sequence encoding at least one structural protein from a Zika virus (ZIKV), a second nucleotide sequence encoding at least one nonstructural protein from a first flavi virus, and a third nucleotide sequence of a (3') untranslated region from a second flavi virus. The multivalent immunogenic compositions comprise an attenuated ZIKV vaccine or an attenuated chimeric ZIKV vaccine (or their combination) together with one or more of a first attenuated virus that is immunogenic against dengue serotype (1), a second attenuated virus that is immunogenic against dengue serotype (2), a third attenuated virus that is immunogenic against dengue serotype (3), and a fourth attenuated virus that is immunogenic against dengue serotype (4). The present disclosure further relates to methods of inducing immune responses, as well as preventing or treating ZIKV infections, and in certain embodiments, the combined prevention or treatment of ZIKV and another flavivirus, e.g., dengue virus.La présente invention concerne des virus Zika atténués et des vaccins contre le virus Zika, des virus Zika chimériques atténués et des vaccins chimériques atténués contre le virus Zika, et des compositions immunogènes multivalentes comprenant des vaccins contre le virus Zika et des vaccins contre d'autres flavivirus. Les virus Zika chimériques comprennent une première séquence nucléotidique codant pour au moins une protéine structurale du virus Zika (ZIKV), une seconde séquence nucléotidique codant pour au moins une protéine non structurale d'un premier flavivirus, et une troisième séquence nucléotidique d'une région non traduite (3') provenant d'un second flavivirus. Les compositions immunogènes multivalentes comprennent un vacci
